NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3oYbzsz
via IFTTT